Literature DB >> 9116013

The photoactivatable inhibitor 7-azido-8-iodoketanserin labels the N terminus of the vesicular monoamine transporter from bovine chromaffin granules.

C Sagné1, M F Isambert, J Vandekerckhove, J P Henry, B Gasnier.   

Abstract

In monoaminergic cells, the hormone or neurotransmitter is concentrated into secretory vesicles by a tetrabenazine- and reserpine-sensitive vesicular monoamine transporter (VMAT), catalyzing a H+/monoamine antiport. Ketanserin is another powerful inhibitor of VMAT that binds to the tetrabenazine binding site. A photoactivatable derivative, 7-azido-8-iodoketanserin (AZIK), labels covalently the transporter from bovine chromaffin granules, VMAT-2. Digestion with endoproteinases V8 or Lys-C, which cleave peptide bonds at acidic or lysine residues, respectively, revealed that the AZIK label is located in a 7 kDa segment of the VMAT-2 polypeptide. The photolabeled chromaffin granule transporter was purified by DEAE and WGA chromatography followed by selective aggregation and size-exclusion HPLC. After treatment by V8 or Lys-C, digestion products were separated by electrophoresis in SDS and sequenced. For both enzymes, the material comigrating with the labeled peptide produced a sequence matching the N terminus of VMAT-2. A K55E mutant of the bovine VMAT-2 cDNA was constructed and expressed in COS-7 cells. The mutant protein exhibited a full VMAT activity and could be labeled by AZIK. However, the formation of the 7 kDa labeled peptide upon Lys-C proteolysis was prevented in the mutant, with a redistribution of the label in higher-molecular mass digestion products. The localization of the label upstream of lysine 55 was confirmed by an immunological and enzymatic analysis. We conclude that the segment 2-55 of bovine VMAT-2, which encompasses the cytosolic N terminus and the first transmembrane segment in the current topological model of the transporter, contains residues involved in the binding of ketanserin and, possibly, tetrabenazine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9116013     DOI: 10.1021/bi9623439

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

1.  The neuronal monoamine transporter VMAT2 is regulated by the trimeric GTPase Go(2).

Authors:  M Höltje; B von Jagow; I Pahner; M Lautenschlager; H Hörtnagl; B Nürnberg; R Jahn; G Ahnert-Hilger
Journal:  J Neurosci       Date:  2000-03-15       Impact factor: 6.167

Review 2.  The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.

Authors:  Justin R Nickell; Kiran B Siripurapu; Ashish Vartak; Peter A Crooks; Linda P Dwoskin
Journal:  Adv Pharmacol       Date:  2014

Review 3.  Vesicular neurotransmitter transporters. Potential sites for the regulation of synaptic function.

Authors:  H Varoqui; J D Erickson
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

Review 4.  Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.

Authors:  Kandatege Wimalasena
Journal:  Med Res Rev       Date:  2010-02-04       Impact factor: 12.944

5.  Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.

Authors:  Yelena Ugolev; Tali Segal; Dana Yaffe; Yael Gros; Shimon Schuldiner
Journal:  J Biol Chem       Date:  2013-09-23       Impact factor: 5.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.